TTRX
Turn Therapeutics Inc.
$6.05
+3.16%
$180.1M
No data for this timeframe.
Vol
Market Cap$180.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders7 funds
Inst. Value$417.4K
Reddit Sentiment71° Bullish
SEC Reports8
Recent Activity
Jun 5, 2026
SEC
Turn Therapeutics announced a peer-reviewed publication in the Journal of Dermatological Treatment showing that GX-03 ac
8-K — Impact 5/10
Jun 4, 2026
Insider
Kester Kent Edward was granted 83,334 shares
Director
Jun 4, 2026
Insider
Dewhurst Martin William was granted 71,666 shares
Director
Jun 4, 2026
Insider
GOLDEN ARTHUR F was granted 89,584 shares
Director
Jun 3, 2026
SEC
Turn Therapeutics released an updated investor presentation at the Jefferies Global Healthcare Conference, disclosing po
8-K — Impact 7/10
Jun 1, 2026
SEC
Turn Therapeutics reported positive interim Phase 2 data for GX-03 in moderate-to-severe atopic dermatitis, showing rapi
8-K — Impact 6/10
Price Targets
$8.00
+63.3% upside
Strong Buy
Current $4.90
Low $8.00
Median $8.00
High $8.00
1 analysts
$8.00
$8.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 24, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Jan 20, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Dec 29, 2025 | D. Boral Capital | INITIATE | Buy |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $158.2K | — |
| BROWN BROTHERS HARRIMAN & | $75.8K | — |
| HighTower Advisors, LLC | $63.0K | — |
| BANK OF AMERICA CORP | $45.2K | — |
| VANGUARD FIDUCIARY TRUST CO | $39.9K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Kester Kent | A | $0.00 |
| Jun 4, 2026 | Dewhurst Martin | A | $0.00 |
| Jun 4, 2026 | GOLDEN ARTHUR | A | $0.00 |
| Jun 4, 2026 | Gengos Andrew | A | $0.00 |
| May 28, 2026 | Burnam Bradley | G | $0.00 |
Reddit Sentiment
71°
Bullish
Bearish
Neutral
Bullish
7 institutional holders with $417.4K total value (130,426 shares) as of 2026-Q1. Top holders: VANGUARD, BROWN, HighTower.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 49,450 | $158.2K | 37.9% | — |
| 2 | BROWN BROTHERS HARRIMAN & CO | 23,688 | $75.8K | 18.2% | — |
| 3 | HighTower Advisors, LLC | 19,684 | $63.0K | 15.1% | — |
| 4 | BANK OF AMERICA CORP /DE/ | 14,124 | $45.2K | 10.8% | — |
| 5 | VANGUARD FIDUCIARY TRUST CO | 12,480 | $39.9K | 9.6% | — |
| 6 | MORGAN STANLEY | 10,000 | $32.0K | 7.7% | — |
| 7 | WELLS FARGO & COMPANY/MN | 1,000 | $3.2K | 0.8% | — |
6 unique insiders with 10 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Kester Kent Edward | Director | AWARD | 83,334 | — | — |
| Jun 4, 2026 | Dewhurst Martin William | Director | AWARD | 71,666 | — | — |
| Jun 4, 2026 | GOLDEN ARTHUR F | Director | AWARD | 89,584 | — | — |
| Jun 4, 2026 | Gengos Andrew | Director | AWARD | 95,000 | — | — |
| May 28, 2026 | Burnam Bradley Evan | Chief Executive Officer | GIFT | 300,000 | — | — |
| Apr 2, 2026 | GOLDEN ARTHUR F | Director | GIFT | 300,000 | — | — |
| Apr 2, 2026 | Burnam Bradley Evan | Chief Executive Officer | GIFT | 300,000 | — | — |
| Apr 1, 2026 | Chaudhary Zuraiz | See Remarks | AWARD | 80,000 | — | — |
| Apr 1, 2026 | Burnam Bradley Evan | Chief Executive Officer | AWARD | 160,000 | — | — |
| Jan 7, 2026 | Dewhurst Martin William | Director | AWARD | 21,882 | — | — |
8 SEC filing reports analyzed. Sentiment: 4 bullish, 1 bearish, 1 mixed, 2 neutral. Avg impact: 5.3/10.
BULLISH
8-K
5/10
Turn Therapeutics announced a peer-reviewed publication in the Journal of Dermatological Treatment s
Jun 5, 2026
BULLISH
8-K
7/10
Turn Therapeutics released an updated investor presentation at the Jefferies Global Healthcare Confe
Jun 3, 2026
BULLISH
8-K
6/10
Turn Therapeutics reported positive interim Phase 2 data for GX-03 in moderate-to-severe atopic derm
Jun 1, 2026
NEUTRAL
8-K
2/10
Turn Therapeutics (TTRX) announced that CEO Bradley Burnam will present at the Jefferies Global Heal
May 19, 2026
BULLISH
8-K
5/10
Turn Therapeutics appointed Dr. Stephen M. Hahn, former FDA Commissioner, as Executive Clinical and
May 18, 2026
NEUTRAL
8-K
4/10
Turn Therapeutics reported Q1 2026 results: net loss of $0.97M ($0.03/share) vs $0.33M ($0.01/share)
May 11, 2026
MIXED
8-K
6/10
Turn Therapeutics reported full-year 2025 financial results with a net loss of $3.19 million, up fro
Apr 21, 2026
BEARISH
EFFECT
7/10
Turn Therapeutics has two effective registration statements (File Nos. 333-290800 and 333-289972) en
Apr 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (86% buy). Based on 7 analysts: 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.00 mean target
+63.3% upside
Strong Buy (1.00)
$8.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $4.90 |
| Target Low | $8.00 |
| Target Mean | $8.00 |
| Target Median | $8.00 |
| Target High | $8.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 24, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 29, 2025 | D. Boral Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
71°
Bullish
Bearish
Neutral
Bullish
3 mentions
3 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
TTRX take a look at their recent board appointments
▲ 1
💬 1
⚡ 0.5
TTRX board
▲ 3
💬 2
⚡ 0.1
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.